***Commonwealth of Massachusetts***

***Executive Office of Health and Human Services***

***Office of Medicaid***

[*www.mass.gov/masshealth*](http://www.mass.gov/masshealth)

MassHealth

# All Provider Bulletin 365

# April 11, 2023

**TO**: All Providers Participating in MassHealth

**FROM**: Mike Levine, Assistant Secretary for MassHealth [signature of Mike Levine]

RE: MassHealth’s Continuing Coverage of Reproductive Health Medications

## Background

The Commonwealth of Massachusetts continues to recognize access to abortion and medical management of miscarriage, including but not limited to the use of mifepristone and misoprostol, as fundamental rights and basic healthcare services. As described below, mifepristone and misoprostol remain fully available in Massachusetts, and MassHealth will continue coverage without prior authorization.

Yesterday, April 10, 2023, Governor Healey signed [Executive Order 609](https://www.mass.gov/doc/protecting-access-to-medicated-abortion) to confirm that the term, “Reproductive health care services,”[[1]](#footnote-1) as defined in the Shield Law ([St.2022, c.127](https://malegislature.gov/Laws/SessionLaws/Acts/2022/Chapter127)), includes the use, prescribing, dispensing, and administration of mifepristone or misoprostol, and directs the Department of Public Health (DPH) and the Board of Registration in Medicine (BORIM) to provide guidance to applicable licensees and licensed health care facilities.

It remains lawful for licensees licensed by DPH Boards and BORIM, as well as licensed health care facilities in the Commonwealth, including hospitals and clinics, to continue using, prescribing, dispensing, or administering mifepristone or misoprostol in the Commonwealth, provided that any such prescribing, dispensing, or administration is done so in accordance with the acceptable standards of care and using sound medical judgment. See [DPH Circular Letter](https://www.mass.gov/info-details/guidance-implementing-executive-order-609)*.*

## MassHealth Continuation of Mifepristone and Misoprostol Coverage without Prior Authorization

MassHealth will continue covering mifepristone (Mifeprex®) and misoprostol (Cytotec®) without prior authorization for all medically necessary treatment, including for medication abortion and medical management of miscarriage, consistent with Governor Healey’s Executive Order and related guidance from DPH and BORIM. Consistent with the standard of care, MassHealth will continue covering medication abortions and medical management of miscarriage using a combined regimen of mifepristone and misoprostol or misoprostol alone, as appropriate.

## MassHealth Website

This bulletin is on the [MassHealth Provider Bulletins](http://www.mass.gov/masshealth-provider-bulletins) web page.

[Sign up](https://www.mass.gov/forms/email-notifications-for-masshealth-provider-bulletins-and-transmittal-letters) to receive email alerts when MassHealth issues new bulletins and transmittal letters.

## Questions

### Dental Services

Phone: (800) 207-5019; TDD/TTY: (800) 466-7566

### Long-Term Services and Supports

Phone: (844) 368-5184 (toll free)

Email: support@masshealthltss.com

Portal: MassHealthLTSS.com

Mail: MassHealth LTSS, PO Box 159108, Boston, MA 02215

Fax: (888) 832-3006

### All Other Provider Types

Phone: (800) 841-2900; TDD/TTY: 711

Email: provider@masshealthquestions.com

1. “Reproductive health care services” is defined as all supplies, care, and services of a medical, behavioral health, mental health, surgical, psychiatric, therapeutic, diagnostic, preventative, rehabilitative, or supportive nature relating to pregnancy, contraception, assisted reproduction, miscarriage management, or the termination of a pregnancy. [↑](#footnote-ref-1)